LPCN

Live webinar to take place on Friday, June 12, 2026 at 11:00 AM Eastern Time SALT LAKE CITY, June 4, 2026 /PRNewswire/ -- Lipocine Inc. (Nasdaq: LPCN), a specialty pharmaceutical company focused on the development of novel oral therapeutics, today announced that it will host a virtual Key Opinion Leader (KOL) event on Friday, June 12, 2026 at 11:00 AM Eastern Time. The event will bring together leading physicians with deep expertise in postpartum depression (PPD) to discuss the continued clinical unmet needs in PPD and the emerging clinical profile of LPCN 1154 (BRLIZIO™), Lipocine's investigational oral brexanolone, as a potential differentiated treatment option for women with PPD.

SALT LAKE CITY, May 19, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery, today announced that its Phase 3 clinical data for LPCN 1154 have been selected for oral and poster presentation at the 2026 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting, to be held May 26–29, 2026, in Miami, FL. Oral Presentation details Title: Novel Oral Rapid-Acting Neuroactive Steroid for Treatment of Postpartum Depression: A Placebo-Controlled Phase 3 Clinical Trial of LPCN 1154 Presenter: Benjamin Bruno, PhD, Vice President, Clinical Development, Lipocine Session: Pharmaceutical Pipeline (Oral Presentation) Date: Tuesday, May 26, 2026 Time: 3:20 PM ET Location: Loews Miami Beach Hotel, Miami, FL The presentation will highlight results from Lipocine's Phase 3 placebo-controlled trial evaluating LPCN 1154 (oral brexanolone) for the treatment of postpartum depression (PPD).

BASEL, Switzerland, May 19, 2026 (GLOBE NEWSWIRE) -- Anaveon, a late-stage biotechnology company pioneering precision biologics to reprogram the immune system for the treatment of autoimmune and inflammatory diseases, today announced the appointments of Eric Zanelli, Ph.D., as Chief Scientific Officer and Jill Jene, Ph.D.

SALT LAKE CITY, May 18, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery, today announced that management will participate in a fireside chat at A.G.P.'s Annual Healthcare Company Showcase being held Wednesday, May 20, 2026.

Lipocine (LPCN) came out with a quarterly loss of $0.54 per share versus the Zacks Consensus Estimate of a loss of $0.51. This compares to a loss of $0.35 per share a year ago.

SALT LAKE CITY, May 7, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery, today announced financial results for the first quarter ended March 31, 2026 and provided a corporate update. Neuroactive Steroids (NAS) LPCN 1154 for Postpartum Depression ("PPD") In April 2026, Lipocine announced topline results from its Phase 3 placebo-controlled trial (N=90) evaluating LPCN 1154 (oral brexanolone) for the treatment of postpartum depression.